MX2007014474A
(es)
*
|
2005-05-17 |
2008-02-07 |
Univ Connecticut |
Composiciones y metodos para inmunomodulacion en un organismo.
|
EP1777294A1
(en)
*
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
AP2911A
(en)
|
2005-12-02 |
2014-05-31 |
Sinai School Medicine |
Chimeric Viruses presenting non-native surface proteins and uses thereof
|
NZ596494A
(en)
|
2006-01-13 |
2013-07-26 |
Us Gov Nat Inst Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
WO2008089144A2
(en)
*
|
2007-01-12 |
2008-07-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Improved dna vaccination protocols
|
PT2160401E
(pt)
|
2007-05-11 |
2014-10-30 |
Altor Bioscience Corp |
Moléculas de fusão e variantes de il-15
|
AU2016206235B2
(en)
*
|
2007-06-27 |
2017-04-20 |
Novartis Ag |
Complexes of il-15 and il-15ralpha and uses thereof
|
ES2466916T3
(es)
|
2007-06-27 |
2014-06-11 |
Admune Therapeutics Llc |
Complejos de IL-15 e IL-15R alfa y usos de los mismos
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
JP2013501817A
(ja)
|
2009-08-14 |
2013-01-17 |
アメリカ合衆国 |
胸腺産出の増大およびリンパ球減少症の治療のためのil−15の使用
|
KR20120093163A
(ko)
*
|
2009-09-14 |
2012-08-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Il-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体il−15可溶性融合分子並びにその製造及び使用方法
|
JP2014502258A
(ja)
|
2010-10-22 |
2014-01-30 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
免疫反応を抑制するためにプログラムされた制御性t細胞の発見
|
CA2824515C
(en)
|
2011-01-18 |
2022-09-13 |
Bioniz, Llc |
Compositions and methods for modulating gamma-c-cytokine activity
|
EP2537933A1
(en)
*
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
DK2788021T3
(da)
|
2011-12-09 |
2017-04-10 |
Bavarian Nordic As |
Poxvirusvektor til ekspression af bakterielle antigener, der er koblet til tetanustoksinfragment c
|
JP6234446B2
(ja)
|
2012-06-08 |
2017-11-22 |
アルカーメス,インコーポレイテッド |
ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド
|
US10548957B2
(en)
|
2012-09-28 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
|
EP2911684B1
(en)
*
|
2012-10-24 |
2019-06-19 |
Novartis Ag |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
MX2015011886A
(es)
|
2013-03-14 |
2016-05-31 |
Icahn School Med Mount Sinai |
Virus de la enfermedad de newcastle y usos de los mismos.
|
DK2970486T3
(da)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
Modulering af t-celler med bispecifikke antistoffer og fc-fusioner
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2986312B1
(en)
*
|
2013-04-19 |
2021-12-15 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
KR102095700B1
(ko)
|
2013-05-14 |
2020-04-01 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
|
EP4269441A3
(en)
|
2013-08-08 |
2024-01-24 |
Cytune Pharma |
Il-15 and il-15ralpha sushi domain based on modulokines
|
KR102457731B1
(ko)
*
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
CA2935599A1
(en)
|
2014-01-08 |
2015-07-16 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Il-15 heterodimeric protein and uses thereof
|
HUE057917T2
(hu)
*
|
2014-01-15 |
2022-06-28 |
Kadmon Corp Llc |
Immunmodulátor szerek
|
JP6857498B2
(ja)
|
2014-02-27 |
2021-04-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
癌を処置するための併用方法
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
ME03666B
(me)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
CN106459914B
(zh)
|
2014-05-15 |
2020-11-06 |
新加坡国立大学 |
经修饰的自然杀伤细胞及其用途
|
EP3673915A1
(en)
|
2014-06-30 |
2020-07-01 |
Altor BioScience Corporation |
Il-15-based molecules and methods of use thereof
|
ES2811974T3
(es)
|
2014-07-29 |
2021-03-15 |
Novartis Ag |
Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
|
EP3186274B1
(en)
|
2014-08-27 |
2021-10-06 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
BR112017007379A2
(pt)
|
2014-10-14 |
2017-12-19 |
Dana Farber Cancer Inst Inc |
moléculas de anticorpo para pd-l1 e usos das mesmas
|
KR20170084326A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 종양 항원과 결합하는 이종이량체 항체
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
SI3235830T1
(sl)
*
|
2014-12-19 |
2020-12-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
Proteinski kompleks interlevkina 15 in njegove uporabe
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
ES2923895T3
(es)
|
2015-02-27 |
2022-10-03 |
Icell Gene Therapeutics Llc |
Receptores de antígeno quimérico (CARS) dirigidos a neoplasisas malignas hematológicas, composiciones y métodos de uso de los mismos
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
CA2990177A1
(en)
*
|
2015-06-25 |
2016-12-29 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
WO2017046200A1
(en)
|
2015-09-16 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
|
EP3368658B1
(en)
|
2015-10-30 |
2022-07-06 |
Cancer Research Technology Limited |
Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
EP3430055B1
(en)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
CA3029197A1
(en)
|
2016-06-24 |
2017-12-28 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
WO2018013855A2
(en)
|
2016-07-14 |
2018-01-18 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
PE20191034A1
(es)
*
|
2016-10-14 |
2019-08-05 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
|
CA3200275A1
(en)
|
2016-10-21 |
2018-04-26 |
Nantcell, Inc. |
Multimeric il-15-based molecules
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
WO2018132494A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
KR20190124750A
(ko)
|
2017-02-28 |
2019-11-05 |
사노피 |
치료적 rna
|
CA3056630A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
MX2019011514A
(es)
|
2017-03-27 |
2020-01-27 |
Nat Univ Singapore |
Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
|
US11896616B2
(en)
|
2017-03-27 |
2024-02-13 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
CN111010866A
(zh)
|
2017-05-24 |
2020-04-14 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
US20200223918A1
(en)
*
|
2017-06-21 |
2020-07-16 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
US11524033B2
(en)
|
2017-09-05 |
2022-12-13 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
JP2021505131A
(ja)
*
|
2017-12-08 |
2021-02-18 |
フェイト セラピューティクス,インコーポレイテッド |
増強されたiPSC由来のエフェクター細胞を用いた免疫療法
|
EP3727146A4
(en)
*
|
2017-12-19 |
2021-10-06 |
Blaze Bioscience, Inc. |
CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
TW202003011A
(zh)
|
2018-03-26 |
2020-01-16 |
美商艾爾特生物科技責任有限公司 |
抗PDL1、IL-15及TGF-β受體組合分子
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
CN110437339B
(zh)
*
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
US11912763B2
(en)
|
2018-06-17 |
2024-02-27 |
L & L Biopharma Co., Ltd. |
Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
|
WO2019246379A1
(en)
*
|
2018-06-22 |
2019-12-26 |
Cugene Inc. |
Novel interleukin-15 (1l-15) fusion proteins and uses thereof
|
CN110862967A
(zh)
*
|
2018-08-27 |
2020-03-06 |
天津天锐生物科技有限公司 |
一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
|
CN113015744A
(zh)
*
|
2018-08-30 |
2021-06-22 |
Hcw生物科技公司 |
单链嵌合多肽和多链嵌合多肽以及其用途
|
KR20210069639A
(ko)
|
2018-08-30 |
2021-06-11 |
에이치씨더블유 바이올로직스, 인크. |
단일-사슬 키메라 폴리펩타이드 및 이의 용도
|
JP7479383B2
(ja)
|
2018-09-27 |
2024-05-08 |
エクシリオ デベロップメント, インコーポレイテッド |
マスクされたサイトカインポリペプチド
|
AU2019355971A1
(en)
|
2018-10-03 |
2021-05-06 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
CN113423734A
(zh)
|
2018-10-12 |
2021-09-21 |
Xencor股份有限公司 |
靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
WO2020095058A1
(en)
|
2018-11-08 |
2020-05-14 |
GammaDelta Therapeutics Limited |
Methods for isolating and expanding cells
|
GB201818243D0
(en)
|
2018-11-08 |
2018-12-26 |
Gammadelta Therapeutics Ltd |
Methods for isolating and expanding cells
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
WO2020231855A1
(en)
|
2019-05-10 |
2020-11-19 |
Nant Holdings Ip, Llc |
Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
|
MX2021014189A
(es)
|
2019-05-20 |
2022-01-06 |
Cytune Pharma |
Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
KR20220045019A
(ko)
*
|
2019-08-15 |
2022-04-12 |
아이쥐엠 바이오사이언스 인코포레이티드 |
면역자극성 다량체 결합 분자
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
US20220380487A1
(en)
*
|
2019-10-24 |
2022-12-01 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CN111690068B
(zh)
*
|
2019-11-13 |
2022-04-19 |
中国科学技术大学 |
一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
|
JP2023502712A
(ja)
|
2019-11-21 |
2023-01-25 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法
|
CA3164353A1
(en)
*
|
2019-12-13 |
2021-06-17 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
GB202006989D0
(en)
|
2020-05-12 |
2020-06-24 |
Gammadelta Therapeutics Ltd |
Methods for isolating gamma delta t cells
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
CN114057889B
(zh)
*
|
2020-07-30 |
2023-11-10 |
深圳市北科生物科技有限公司 |
二硫键稳定的IL15-IL15Rα复合物及其应用
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
EP4208476A1
(en)
*
|
2020-09-01 |
2023-07-12 |
Wuxi Biologics Ireland Limited |
Long-acting il-15 and uses thereof
|
MX2023004879A
(es)
|
2020-10-26 |
2023-05-11 |
Cytune Pharma |
AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DEL CARCINOMA DE CÉLULAS ESCAMOSAS.
|
US20230398185A1
(en)
|
2020-10-26 |
2023-12-14 |
Cytune Pharma |
Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
GB202105113D0
(en)
|
2021-04-09 |
2021-05-26 |
Gammadelta Therapeutics Ltd |
Novel method
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
AU2022299404A1
(en)
|
2021-06-23 |
2023-12-07 |
Cytune Pharma |
Interleukin 15 variants
|
KR20240040799A
(ko)
|
2021-08-03 |
2024-03-28 |
감마델타 테라퓨틱스 엘티디 |
감마 델타 t 세포 및 이의 조성물의 조작
|
EP4384204A1
(en)
|
2021-08-13 |
2024-06-19 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
|
CN116829578A
(zh)
*
|
2021-10-08 |
2023-09-29 |
苏州艾博生物科技有限公司 |
编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
WO2023194911A1
(en)
|
2022-04-04 |
2023-10-12 |
Gammadelta Therapeutics Ltd |
Cells expressing an anti-mesothelin car
|
GB202204926D0
(en)
|
2022-04-04 |
2022-05-18 |
Gammadelta Therapeutics Ltd |
Method for expanding gammadelta T cells
|
WO2023194915A1
(en)
|
2022-04-04 |
2023-10-12 |
Gammadelta Therapeutics Ltd |
Novel gene armoring
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|